“Real world” efficacy of bulevirtide in <scp>HBV</scp>/<scp>HDV</scp>‐related cirrhosis including people living with <scp>HIV</scp>: Results from the compassionate use programme at <scp>INMI</scp> Spallanzani in Rome, Italy

Abstract

Preliminary results suggest that bulevirtide is feasible and well-tolerated in populations with difficult-to-treat conditions, such as those with HIV/HBV/HDV co-infection and migrants, when special attention is given to patient education. HDV-RNA decline during treatment was similar in people living with and without HIV.